You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
億勝生物科技(01061.HK)年度淨利潤減少27.6%至2.19億港元 末期息5港仙
格隆匯 03-12 21:34

格隆匯3月12日丨億勝生物科技(01061.HK)發佈公吿,截至2020年12月31日止年度,公司營業額9.78億港元,同比減少23.6%;期間利潤2.19億港元,同比減少27.6%;每股盈利37.88港仙,末期股息每股5港仙。

收益減少乃歸因於2020年上半年減少約44.3%,原因為中國多個省市政府實施一系列控制措施以遏制COVID-19擴散,這對中國醫院的門診運作造成重大影響,並阻礙非緊急病人前往醫院及門診診所。然而,由於中國醫院門診運作已於2020年九月大致恢復正常,集團的收益亦已自第三季度起恢復至接近COVID-19之前的水平。有關恢復有助將下半年的收益較去年同期跌幅降至約6.2%。

於2020年12月31日,共有15項研發計劃處於臨牀前至臨牀階段,其中4項眼科計劃處於新藥臨牀試驗申請(IND)╱臨牀╱新藥上市申請階段。於本公佈日期,集團持有合共34份專利證書或授權書,包括27項發明專利、3項實用新型專利及4項外觀專利。

數年來,集團一直不懈投入資源積蓄及強化其市場渠道能力。於2020年12月31日,集團於中國部署43間地區銷售辦事處網絡及總數約1,290名銷售人員及營銷代表,其中約38%為合約人員或代理聘請人員。於回顧年度,集團的治療產品主要於中國主要城市、省份及縣城的逾9,000家醫院及醫療機構以及約2,000家藥房處方。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account